Table 2.
Demographic and clinical characteristics of SLE patients and healthy controls.
| Characteristics | Cohort1 |
Cohort2 |
||
|---|---|---|---|---|
| SLE (n = 33) | HC (n = 23) | SLE (n = 25) | HC (n = 30) | |
| Demographic characteristics | ||||
| Female/male | 30/3 | 23/0 | 20/5 | 23/7 |
| Median age (years) (IQR) | 37 (19–72) | 33 (23–54) | 35 (18–74) | 31.3 (24–55) |
| Clinical features | ||||
| Disease duration (year) (median) (IQR) | 6 (1–27) | / | 3 (1–18) | / |
| SLEDAI (median) (IQR) | 9 (0–24) | / | 10 (2–22) | / |
| Inactive patients (n) (%) | 7 (21.21) | / | 5 (20) | / |
| Active patients (n) (%) | 26 (78.79) | / | 20 (80) | / |
| Clinical manifestations (n) (%) | ||||
| Rash | 14 (42.42) | / | 10 (40) | / |
| Photosensitivity | 9 (27.27) | / | 5 (20) | / |
| Oral ulcers | 5 (15.15) | / | 3 (12) | / |
| Alopecia | 9 (27.27) | / | 7 (28) | / |
| Arthritis | 11 (33.33) | / | 3 (12) | / |
| Serositis | 6 (18.18) | / | 3 (12) | / |
| Renal involvement | 15 (45.45) | / | 13 (52) | / |
| Neurological involvement | 3 (9.09) | / | 1 (4) | / |
| Leukopenia | 6 (18.18) | / | 8 (32) | / |
| Lymphopenia | 12 (36.36) | / | 12 (48) | / |
| Thrombocytopenia | 7 (21.21) | / | 2 (8) | / |
| ANA positive | 29 (87.88) | / | 22 (88) | / |
| Anti-dsDNA positiv | 22 (66.67) | / | 16 (64) | / |
| Anti-Sm positive | 13 (39.40) | / | 6 (24) | / |
| Anti-Phospholipid positive | 5 (15.15) | / | 4 (16) | / |
| Low Complement | 16 (48.48) | / | 11 (44) | / |
| Treatment (n) (%) | ||||
| Prednisolone | 22 (66.67) | / | 12 (48) | / |
| Hydroxychloroquine | 18 (54.55) | / | 10 (40) | / |
| Azathioprine | 3 (9.09) | / | 0 (0) | / |
| Vitamin D | 4 (12.12) | / | 0 (0) | / |
| Baricitinib | 1 (3.03) | / | 0 (0) | / |
| Sirolimus | 0 (0) | / | 0 (0) | / |
| Metformin | 0 (0) | / | 0 (0) | / |
Patients with a SLEDAI score of ≥5 were classified as active state, as inactive groups referred to the patients with the score of ≤4. IQR, inter quartile range.
Continuous variables are represented as mean ± standard deviation (SD).